Hiroki Maekawa
Finanzdirektor/CFO bei KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.
Profil
Hiroki Maekawa is currently the Chief Financial Officer & Director at Kubota Pharmaceutical Holdings Co. Ltd.
since 2019 and the Chief Financial Officer at Acucela, Inc. since 2018.
Previously, he held positions as the CFO, Director & Head-Investor Relations at SymBio Pharmaceuticals Ltd.
in 2013, and as a Principal at Nippon Life Insurance Co., ASKA Pharmaceutical Co., Ltd., and Sosei Group Corp.
He completed his undergraduate degree in Economics from Doshisha University Faculty of Economics in 1990.
Aktive Positionen von Hiroki Maekawa
Unternehmen | Position | Beginn |
---|---|---|
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. | Finanzdirektor/CFO | 01.06.2018 |
ACUCELA INC | Finanzdirektor/CFO | 01.11.2018 |
Ehemalige bekannte Positionen von Hiroki Maekawa
Unternehmen | Position | Ende |
---|---|---|
ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology ASKA Pharmaceutical Co., Ltd. engages in the manufacture, sale, import, and export of pharmaceuticals, veterinary medicine, quasi-drugs, food, and medical devices. It operates through the Pharmaceutical Business and Other segments. The Pharmaceutical Business segment manufactures and sells medical drugs. The Other segment includes veterinary drugs, clinical testing, and medical devices. The company was founded by Yasohachi Yamaguchi on June 16, 1920 and is headquartered in Tokyo, Japan. | Corporate Officer/Principal | - |
NXERA PHARMA CO., LTD. | Corporate Officer/Principal | - |
Nippon Life Insurance Co.
Nippon Life Insurance Co. Life/Health InsuranceFinance Nippon Life Insurance Co. engages in the provision of life insurance services, agency or administration services to other insurance companies and financial institutions. It also provides the guarantees for liabilities, sale and purchase of government bonds and local government bonds, and sales of investment trust beneficiary securities. The company was founded by Sukesaburo Hirose on July 4, 1889 and is headquartered in Osaka, Japan. | Corporate Officer/Principal | - |
SYMBIO PHARMACEUTICALS LIMITED | Finanzdirektor/CFO | 03.04.2013 |
Ausbildung von Hiroki Maekawa
Doshisha University Faculty of Economics | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
SYMBIO PHARMACEUTICALS LIMITED | Health Technology |
NXERA PHARMA CO., LTD. | Health Technology |
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. | Health Technology |
Private Unternehmen | 3 |
---|---|
Nippon Life Insurance Co.
Nippon Life Insurance Co. Life/Health InsuranceFinance Nippon Life Insurance Co. engages in the provision of life insurance services, agency or administration services to other insurance companies and financial institutions. It also provides the guarantees for liabilities, sale and purchase of government bonds and local government bonds, and sales of investment trust beneficiary securities. The company was founded by Sukesaburo Hirose on July 4, 1889 and is headquartered in Osaka, Japan. | Finance |
ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology ASKA Pharmaceutical Co., Ltd. engages in the manufacture, sale, import, and export of pharmaceuticals, veterinary medicine, quasi-drugs, food, and medical devices. It operates through the Pharmaceutical Business and Other segments. The Pharmaceutical Business segment manufactures and sells medical drugs. The Other segment includes veterinary drugs, clinical testing, and medical devices. The company was founded by Yasohachi Yamaguchi on June 16, 1920 and is headquartered in Tokyo, Japan. | Health Technology |
Acucela, Inc.
Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |